Postmarketing surveillance for drug abuse

Area of Science:

• Pharmacovigilance and Drug Safety
• Public Health Surveillance
• Pharmaceutical Policy

Background:

• Accurate assessment of prescribed medication abuse necessitates robust postmarketing surveillance.
• Current postmarketing surveillance systems, as of 2002 in the United States, require enhancement.
• Medication-specific surveillance systems offer potential improvements but have limitations.

Purpose of the Study:

• To review general postmarketing surveillance systems in the US.
• To evaluate two specific medication-surveillance systems.
• To identify limitations and areas for improvement in postmarketing surveillance.

Main Methods:

• Review of general postmarketing surveillance systems in the United States.
• Description and comparison of two medication-specific surveillance systems.
• Analysis of limitations and validation challenges.

Main Results:

• General postmarketing surveillance systems were in their early stages of development in 2002.
• Two medication-specific systems were tested, revealing specific strengths and weaknesses.
• Comparator medication data is essential for validating surveillance systems and contextualizing findings.

Conclusions:

• Postmarketing surveillance is an evolving field requiring further research.
• Improving the validity of surveillance systems without encouraging illicit experimentation is a key challenge.
• Incorporating comparator medication data is vital for enhancing the reliability and interpretability of postmarketing surveillance.